Department of Chemistry, ShahJalal University of Science and Technology, Sylhet 3114, Bangladesh.
CPBN, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.
Life Sci. 2021 Jun 1;274:119337. doi: 10.1016/j.lfs.2021.119337. Epub 2021 Mar 11.
RNA interference (RNAi) represents a promising therapeutic method that uses siRNA for cancer treatment. Although the RNAi technique has been increasingly used for clinical trials, systemic siRNA delivery into targeted cells is still challenging. The barriers impeding siRNA therapeutics delivery and impacting the treatment outcome must overcome with negligible systemic toxicity for a desirable and successful delivery of siRNA to MDR cancer cells. Nano delivery strategies have been investigated for nanocarrier functionalization, cancer immunotherapy and cancer targeting. Lipid nanoparticles (LNPs), dynamic polyconjugates (DPC™), GalNAc-siRNA conjugates, exosome and RBC systems have shown potential for efficient delivery of siRNA to cancer cells. Delivery of siRNA to tumor cells, immune cells to regulate T cell functions for immunotherapy are promising approaches.
RNA 干扰 (RNAi) 代表了一种有前途的治疗方法，它使用 siRNA 来治疗癌症。尽管 RNAi 技术已越来越多地用于临床试验，但将 siRNA 递送到靶向细胞仍然具有挑战性。必须克服阻碍 siRNA 治疗药物递送至影响治疗效果的障碍，同时对系统具有可忽略的毒性，以实现理想和成功地将 siRNA 递送至多药耐药性癌细胞。纳米传递策略已被用于研究纳米载体的功能化、癌症免疫疗法和癌症靶向。脂质纳米颗粒 (LNPs)、动态聚缀合物 (DPC™)、GalNAc-siRNA 缀合物、外泌体和 RBC 系统已显示出将 siRNA 有效递送至癌细胞的潜力。将 siRNA 递送至肿瘤细胞、免疫细胞以调节 T 细胞功能进行免疫治疗是很有前途的方法。
